Table 6.
Continuation Pharmacotherapy Group | ||||
---|---|---|---|---|
NT-Li | VEN-Li | |||
Mean | SD | Mean | SD | |
Average Oral Dosage (mg) | ||||
NT | 87.63 | 27.78 | 86.51* | 21.18 |
VEN | 286.74* | 29.60 | 275.20 | 37.42 |
Li | 686.91 | 219.19 | 664.08 | 242.10 |
Maximum Oral Dosage (mg) | ||||
NT | 99.11 | 30.88 | 93.85* | 23.57 |
VEN | 294.64* | 24.17 | 291.39 | 30.92 |
Li | 816.96 | 285.92 | 784.43 | 300.49 |
Average Blood Level | ||||
NT (ng/ml) | 107.99 | 45.68 | 104.80* | 30.06 |
Li (mEq/L) | 0.51 | 0.16 | 0.48 | 0.17 |
Maximum Blood Level | ||||
NT (ng/ml) | 154.60 | 69.93 | 122.77* | 33.22 |
Li (mEq/L) | 0.71 | 0.23 | 0.68 | 0.27 |
NT = nortriptyline; VEN = venlafaxine; Li = lithium carbonate.
For patient not receiving a medication (e.g., NT for patients treated with VEN-Li) oral dosage reflects the dosage believed to be administered and blood levels reflect dummy values reported to the treating physician.